


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



溫州康寧醫院
Wenzhou Kangning Hospital Co., Ltd.

(A joint stock limited liability company incorporated in the People's Republic of China)

Stock code: 220

VOLUNTARY ANNOUNCEMENT PRINCIPAL OPERATING DATA AND INDICATORS FOR THE YEAR ENDED DECEMBER 31, 2023 AND THE FOURTH QUARTER 2023

This is a voluntary announcement made by Wenzhou Kangning Hospital Co., Ltd. (the “**Company**”) to keep the shareholders of the Company and potential investors informed of the latest business developments of the Company and its subsidiaries (the “**Group**”).

The table below sets forth the relevant operating data and indicators of the Group’s owned hospitals by inpatients and outpatients for the year ended December 31, 2023 with comparative figures for the year ended December 31, 2022:

	For the year ended December 31,		
	2023	2022	Year-on-year changes
Inpatients			
Number of inpatient bed-days	3,471,334	3,134,950	10.7%
Average inpatient spending per bed-day on treatment and general healthcare services (RMB)	330	341	-3.2%
Average inpatient spending per bed-day on pharmaceutical sales (RMB)	50	51	-2.0%
Total average inpatient spending per bed-day (RMB)	380	392	-3.1%
Outpatients			
Number of outpatient visits	501,214	454,118	10.4%
Average outpatient spending per visit on treatment and general healthcare services (RMB)	133	123	8.1%
Average outpatient spending per visit on pharmaceutical sales (RMB)	298	325	-8.3%
Total average outpatient spending per visit (RMB)	431	448	-3.8%

The table below sets forth the relevant operating data and indicators of the Group's owned hospitals by inpatients and outpatients for the three months (the fourth quarter) from October 1, 2023 to December 31, 2023 with comparative figures of the same period in 2022:

	Three months from October 1 to December 31,		
	2023	2022	Year-on-year changes
Inpatients			
Number of inpatient bed-days	937,828	810,315	15.7%
Average inpatient spending per bed-day on treatment and general healthcare services (<i>RMB</i>)	310	341	-9.1%
Average inpatient spending per bed-day on pharmaceutical sales (<i>RMB</i>)	<u>47</u>	<u>55</u>	<u>-14.5%</u>
Total average inpatient spending per bed-day (<i>RMB</i>)	<u>357</u>	<u>396</u>	<u>-9.8%</u>
Outpatients			
Number of outpatient visits	122,496	111,825	9.5%
Average outpatient spending per visit on treatment and general healthcare services (<i>RMB</i>)	129	123	4.9%
Average outpatient spending per visit on pharmaceutical sales (<i>RMB</i>)	<u>318</u>	<u>339</u>	<u>-6.2%</u>
Total average outpatient spending per visit (<i>RMB</i>)	<u>447</u>	<u>462</u>	<u>-3.2%</u>

Note:

1. The above total average inpatient spending per bed-day is determined based on the Company's bills for services provided to patients, without taking into account differences with medical insurance settlements and the Company's income deduction for some medical expenses that may not be received.

The above operating data and indicators are based on the Company's records and have not been audited or reviewed by the Company's auditors. The operating data may be different from those disclosed in relevant periodical reports. The operating data disclosed in relevant periodical reports shall prevail if there is any discrepancy. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

Shareholders and potential investors of the Company are reminded to rationally deal with any information not officially released by the Company, and shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

By order of the Board
Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili
Chairman

Zhejiang, the PRC
January 3, 2024

As at the date of this announcement, the Company's executive directors are Mr. GUAN Weili, Ms. WANG Lianyue and Mr. WANG Jian; the non-executive directors are Mr. QIN Hao and Mr. LI Changhao; and the independent non-executive directors are Ms. ZHONG Wentang, Ms. JIN Ling and Mr. CHAN Sai Keung Hugo.